With passage of the nuclear liability Bill, the heavy engineering supply chain, led by Bharat Heavy Electricals Ltd (BHEL), Larsen & Toubro (L&T) and Bharat Forge Ltd (BFL), is gearing to take up the challenge ahead.
In a twist to the tale of drug patent infringement cases in the United States, Indian drug company Lupin has sued Ranbaxy Laboratories, which is now controlled by Japanese drug major Daiichi Sankyo, in an American court.
India Inc's bear hug with Russian consumers is getting warmer. From selling marquee cars to liquor, the relationship is heading into the next league -- joint ventures in diverse areas such as petrochemicals, telecom, pharmaceuticals and nanotechnology.
Over 550,000 small drug retailers in the country are transforming into producers and marketers of pharmaceutical products, readying to compete with companies such as Ranbaxy, Cipla, Sun Pharma and Lupin whose produce they sell.
Employment exchanges will not remain mere places where people register their names and begin an endless wait for a call for an interview for a job which, most often, may never happen.
L&T plans to transfer the equity of L&T in their joint ventures with Mitsubishi Heavy Industries into L&T Power through a book transfer, if clauses for the re-tender remain the same, company executives told Business Standard.
Plans to set up an integrated pharma firm in a phased manner.
Mukesh Ambani's Reliance Industries Ltd may be one of the biggest producers of natural gas in the country, but its power foray is likely to be coal or renewable energy based. The company is planning to not only bid for ultra mega power projects but also go in for acquisition of the power plants, said industry sources.
US-based Abbott Laboratories has sued Sun Pharmaceutical Industries and Ranbaxy Laboratories in courts there for challenging the patents of its cholesterol-lowering drugs, Niaspan and TriCor, respectively, in separate infringement suits.
The Aditya Birla Group has received in-principle approval from the Kerala government to set up a Rs 4,000-crore (Rs 40 billion) IT and Biotech Knowledge Park and a branch of Birla Institute of Technology and Sciences (BITS) at Kozhikode.
Larsen & Toubro, India's largest engineering, construction and technology company, is aggressively expanding its footprint across various places abroad
Pfizer, the world's largest drug company, and Wyeth have sued Daiichi Sankyo-owned Ranbaxy Laboratories in a US court for infringing the patent rights of Wyeth's drug, Rapamune.
Schools in the information technology capital and its surrounding areas see red over the implementation of the Right of Children to Free and Compulsory Education Act, 2009. They say it is against the prevailing state laws and plan to move court to stop the government from "imposing an additional burden on schools".
Elder Pharma employs about 3,300 people in India, with about 2,700 professionals in marketing and sales. This recruitment will help Elder Pharma to have one of the largest drug sales force in India, like market leaders such as Cipla, Ranbaxy, Piramal Healthcare and Lupin.
Indian IT companies are equally jubilant. That's because the Bill, which proposes to create Electronic Health Records (EHRs) for all Americans by 2014, is expected to open up a $20 billion market opportunity for Indian IT services firms like Infosys, Wipro, TCS, Firstsource and MindTree.
Cephalon, a US-based drug maker, has filed a lawsuit against Lupin Ltd and its US subsidiary Lupin Pharmaceuticals for challenging the patents on its sleep disorder drug Nuvigil.
Andrew Witty, chief executive of GlaxoSmithKline (GSK), the world's second-largest drug company, was in India this week as part of the dedication of an albandazole manufacturing facility at Nashik to the World Health Organization (WHO)'s global programme to eliminate Lymphatic Filariasis.
If most of the top 10 Indian drug companies were less than Rs 500-crore (Rs 5-billion) turnover ones a decade earlier and were focused only on domestic business, now they are companies with annual businesses ranging from Rs 2,000-Rs 6,000 crore (Rs 20-60 billion) and with operations spanning 60-100 countries and employing 3,000-5,000 people.
An analysis of the growth rate of 15 leading drug companies for the third quarter of 2008-09 show excellent performances in domestic turf have been often marred by the poor show of their acquired assets.
Reduced hiring in the US market due to the lingering impact of the global financial crisis has resulted in a spike in the number of non-resident Indian resumes received by Indian human resources (HR) companies. Over 15,000 NRI resumes have accumulated in the inboxes of headhunters, and the number is set to increase, say HR executives.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances